Psychology Quiz: Psychopharmacology
20 questions · exam conditions
0:00
PsychopharmacologyQuestion 1 of 20

Stimulant medications like methylphenidate are often effective in reducing the core symptoms of ADHD, such as inattention and impulsivity. Conceptually, their primary therapeutic effect in relevant brain regions like the prefrontal cortex is achieved by:

selectively increasing the presynaptic release of serotonin, which has a calming effect.
acting as a potent antagonist at postsynaptic dopamine receptors to reduce distracting signals.
blocking the reuptake of dopamine and norepinephrine from the synaptic cleft.
promoting the enzymatic breakdown of excess catecholamines by monoamine oxidase.
← Back to quizzes

Psychology Quiz

Psychology Quiz: Psychopharmacology

Practice Psychopharmacology in Psychology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Psychopharmacology, giving you a quick way to practice the rules, question types, and explanations that matter most for Psychology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Stimulant medications like methylphenidate are often effective in reducing the core symptoms of ADHD, such as inattention and impulsivity. Conceptually, their primary therapeutic effect in relevant brain regions like the prefrontal cortex is achieved by:

  1. selectively increasing the presynaptic release of serotonin, which has a calming effect.
  2. acting as a potent antagonist at postsynaptic dopamine receptors to reduce distracting signals.
  3. blocking the reuptake of dopamine and norepinephrine from the synaptic cleft. (correct answer)
  4. promoting the enzymatic breakdown of excess catecholamines by monoamine oxidase.
Explanation: The correct answer is C. The primary mechanism of action for methylphenidate and amphetamines, the two main classes of stimulants used for ADHD, is the blockade of the dopamine transporter (DAT) and norepinephrine transporter (NET). This action prevents the reuptake of these neurotransmitters from the synapse, increasing their availability and enhancing signaling in brain circuits crucial for executive function and attention. (A) is incorrect as serotonin is not the primary target. (B) is incorrect as stimulants are agonists or reuptake inhibitors, not antagonists; they increase, not decrease, dopamine signaling. (D) is the opposite of the mechanism of MAOIs and is not how stimulants work.

Question 2

A primary mechanism of action for many antipsychotic drugs involves molecules that bind to dopamine D2 receptors in the mesolimbic pathway. This binding prevents endogenous dopamine from attaching to the receptor and does not trigger the receptor's typical intracellular response. This action of 'blocking' the receptor is best described as:

  1. Reuptake inhibition
  2. Partial agonism
  3. Inverse agonism
  4. Antagonism (correct answer)
Explanation: The correct answer is D. An antagonist is a substance that binds to a receptor but does not activate it. By occupying the receptor's binding site, it blocks the endogenous neurotransmitter (in this case, dopamine) from binding and eliciting its effect. This is the classic mechanism of first-generation antipsychotics. (A) is incorrect; reuptake inhibition would increase synaptic dopamine. (B) is incorrect; a partial agonist binds and causes a response that is weaker than the full agonist. (C) is a plausible but less accurate distractor; an inverse agonist binds to the same receptor and produces a pharmacological response opposite to that of an agonist. Simple blocking without intrinsic activity is best defined as antagonism.

Question 3

After several years of pharmacotherapy for a chronic psychotic disorder, a patient develops involuntary, repetitive movements of the facial muscles, including grimacing, lip-smacking, and tongue protrusion. These movements persist even after the medication is discontinued. Which of the following treatments is the most likely cause of this condition?

  1. Long-term use of a first-generation antipsychotic like haloperidol. (correct answer)
  2. High-dose therapy with a benzodiazepine like lorazepam.
  3. Chronic treatment with a mood stabilizer like lithium.
  4. An overdose of a selective serotonin reuptake inhibitor (SSRI) like fluoxetine.
Explanation: The correct answer is A. The symptoms described are characteristic of tardive dyskinesia (TD), a serious and often irreversible movement disorder. TD is a well-known risk associated with long-term use of dopamine receptor antagonists, particularly the older, first-generation (or 'typical') antipsychotics. (B) is incorrect; while benzodiazepines can cause dependence and withdrawal, they do not cause tardive dyskinesia. (C) is incorrect; lithium toxicity can cause tremor and other neurological signs, but not the classic oro-buccal-lingual dyskinesia of TD. (D) is incorrect; an SSRI overdose is associated with serotonin syndrome, not TD.

Question 4

A patient who has been successfully treated for panic disorder with paroxetine for one year stops the medication abruptly due to a perceived lack of need. Two days later, they present with intense dizziness, nausea, lethargy, and strange 'electric shock' sensations in their head (also known as 'brain zaps'). Which is the most accurate interpretation of these symptoms?

  1. These symptoms indicate a rapid and severe relapse of the underlying panic disorder.
  2. This is an antidepressant discontinuation syndrome due to the sudden cessation of the medication. (correct answer)
  3. The patient is likely experiencing a paradoxical reaction where the medication's anxiolytic effects are reversed.
  4. These are signs of serotonin syndrome caused by a rebound surge in serotonin after stopping the drug.
Explanation: The correct answer is B. The cluster of symptoms described, especially the unique 'electric shock' sensations, is highly characteristic of antidepressant discontinuation syndrome. This syndrome is common after abrupt cessation of SSRIs, particularly those with a shorter half-life like paroxetine. (A) is less likely; while a relapse can occur, the specific neurological symptoms are not typical of panic disorder itself. (C) is an incorrect use of the term 'paradoxical reaction.' (D) is incorrect; serotonin syndrome is caused by an excess of serotonin (e.g., from an overdose or drug interaction), not by withdrawal from an SSRI.

Question 5

A patient with Bipolar I Disorder has been treated with lithium for two years. Despite consistent adherence and therapeutic blood levels, the patient continues to experience severe manic episodes. Which of the following represents the most appropriate and evidence-based next step in the patient's psychopharmacological management?

  1. Increasing the lithium dose significantly above the standard therapeutic range to achieve a stronger effect.
  2. Adding a selective serotonin reuptake inhibitor (SSRI) to the lithium to manage mood lability.
  3. Discontinuing lithium and initiating treatment with a stimulant medication to improve cognitive control.
  4. Augmenting or replacing the lithium with an anticonvulsant medication, such as valproic acid or lamotrigine. (correct answer)
Explanation: The correct answer is D. When a patient with bipolar disorder does not respond adequately to lithium (a first-line mood stabilizer), a common and evidence-based strategy is to switch to or add another mood stabilizer, such as an anticonvulsant (e.g., valproic acid, carbamazepine, lamotrigine) or an atypical antipsychotic. (A) is incorrect and dangerous, as it would risk lithium toxicity due to its narrow therapeutic window. (B) is incorrect because antidepressants, particularly when used without a robust mood stabilizer, can induce mania or rapid cycling in patients with Bipolar I Disorder. (C) is incorrect because stimulants can also precipitate or worsen manic symptoms.

Question 6

A patient is prescribed alprazolam (half-life ≈ 12 hours) for occasional panic attacks, and another patient is prescribed fluoxetine (half-life ≈ 5 days) for major depressive disorder. Both patients take their medication once daily and both accidentally miss a single dose. Which outcome is most probable based on the pharmacokinetics of these drugs?

  1. The alprazolam patient is more likely to experience acute withdrawal symptoms and a recurrence of anxiety. (correct answer)
  2. The fluoxetine patient will experience a more severe discontinuation syndrome than the alprazolam patient.
  3. Both patients are likely to experience significant adverse effects of equal severity due to the missed dose.
  4. The fluoxetine patient is more likely to experience a rebound of depressive symptoms within 24 hours.
Explanation: The correct answer is A. A drug's half-life determines how quickly its concentration in the plasma decreases. Alprazolam's short half-life means its levels will drop significantly after missing one dose, leading to potential inter-dose withdrawal or rebound anxiety. Fluoxetine's very long half-life provides a 'tapering' effect, so a single missed dose will cause only a very small drop in plasma concentration, making immediate effects unlikely. (B) and (D) are incorrect because the long half-life of fluoxetine protects against immediate effects from a missed dose. (C) is incorrect because the difference in half-life will lead to very different outcomes.

Question 7

A patient being treated for atypical depression is brought to the emergency room with a sudden, severe occipital headache, palpitations, and a blood pressure of 210/120 mmHg. The patient mentions they just came from a party where they ate aged cheeses and drank red wine. Their symptoms are most likely a reaction caused by their medication inhibiting the breakdown of which substance found in the food?

  1. Tyramine, leading to a hypertensive crisis. (correct answer)
  2. Tryptophan, leading to serotonin syndrome.
  3. Glutamate, leading to an excitotoxic reaction.
  4. Histamine, leading to an anaphylactic reaction.
Explanation: The correct answer is A. This is the classic presentation of a hypertensive crisis caused by the interaction between a Monoamine Oxidase Inhibitor (MAOI) antidepressant and tyramine-rich foods. MAOIs block the enzyme that breaks down tyramine. When tyramine is ingested, it builds up and acts as a potent adrenaline-like substance, causing a massive release of norepinephrine and a dangerous spike in blood pressure. (B) is incorrect; serotonin syndrome is caused by excess serotonin, and while tryptophan is a precursor, this food interaction is not the typical cause. (C) and (D) describe different pathophysiological processes not associated with this specific drug-food interaction.

Question 8

A patient taking a second-generation antipsychotic develops hyperphagia (excessive hunger), significant weight gain, and new-onset type 2 diabetes. These specific metabolic side effects are most strongly associated with the drug's potent antagonist activity at which pair of receptors?

  1. Dopamine D2 and acetylcholine M1 receptors
  2. GABA-A and serotonin 5-HT1A receptors
  3. Norepinephrine alpha-1 and dopamine D4 receptors
  4. Serotonin 5-HT2C and histamine H1 receptors (correct answer)
Explanation: When you encounter questions about antipsychotic side effects, focus on how these medications interact with multiple neurotransmitter systems beyond just dopamine. Second-generation antipsychotics are "dirty drugs" that affect numerous receptors, and understanding which receptors cause specific side effects is crucial. The metabolic syndrome described here—hyperphagia, weight gain, and diabetes—results from antagonism at serotonin 5-HT2C and histamine H1 receptors. 5-HT2C receptors normally suppress appetite and promote satiety; blocking them leads to increased hunger and overeating. H1 receptors regulate wakefulness and metabolism; their antagonism causes sedation and slows metabolic rate, promoting weight gain. Together, these effects create the perfect storm for metabolic dysfunction. Option A is incorrect because while D2 antagonism causes the therapeutic antipsychotic effects, and M1 antagonism causes anticholinergic effects (dry mouth, constipation), neither directly causes metabolic problems. Option B is wrong because GABA-A and 5-HT1A receptors aren't primary targets of antipsychotics and don't mediate these metabolic effects. Option C misses the mark because alpha-1 antagonism mainly causes orthostatic hypotension, and D4 receptors have minimal clinical significance for side effects. Study tip: Remember the receptor-side effect pairs for antipsychotics: H1 = weight gain/sedation, 5-HT2C = appetite increase, M1 = anticholinergic effects, alpha-1 = hypotension, D2 = movement disorders. This pattern appears frequently on psychology exams testing psychopharmacology.

Question 9

A patient who has been stable on a high dose of the SSRI fluoxetine for depression decides to also start taking an over-the-counter herbal supplement, St. John's Wort, which also has serotonergic properties. A few days later, they present to the emergency department with confusion, agitation, muscle twitching (myoclonus), shivering, and a high fever. This clinical picture is most indicative of:

  1. Neuroleptic malignant syndrome.
  2. Serotonin syndrome. (correct answer)
  3. Antidepressant discontinuation syndrome.
  4. A paradoxical anxiety reaction.
Explanation: The correct answer is B. This is a classic presentation of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system. It is often caused by combining two or more serotonergic drugs, such as an SSRI and St. John's Wort. The symptoms form a triad of cognitive changes (confusion, agitation), autonomic instability (fever, shivering), and neuromuscular hyperactivity (myoclonus). (A) is incorrect; NMS is associated with antipsychotics and characterized by lead-pipe rigidity. (C) is incorrect as it's caused by stopping, not adding, a medication. (D) is incorrect as the symptom cluster, particularly the fever and myoclonus, points to a systemic toxicity rather than a purely psychological reaction.

Question 10

A new drug for depression is found to significantly prolong the duration that serotonin remains in the synaptic cleft, thereby increasing the activation of postsynaptic receptors. Laboratory studies confirm that the drug molecule does not bind directly to any serotonin receptors, nor does it alter the function of the enzymes that catabolize serotonin. How is this drug most likely classified?

  1. A direct serotonin agonist
  2. A selective serotonin reuptake inhibitor (SSRI) (correct answer)
  3. A monoamine oxidase inhibitor (MAOI)
  4. A serotonin releasing agent
Explanation: The correct answer is B. The description matches the mechanism of an SSRI, which works by binding to the presynaptic serotonin transporter protein, blocking the reuptake of serotonin from the synapse and thus increasing its availability. (A) is incorrect because a direct agonist would bind to and activate postsynaptic receptors. (C) is incorrect because an MAOI would inhibit the enzyme (monoamine oxidase) that breaks down serotonin, which the stem explicitly rules out. (D) is incorrect because a releasing agent would actively promote the release of serotonin from the presynaptic terminal, a different mechanism.

Question 11

Two patients with identical symptoms of major depression are prescribed the same starting dose of citalopram. After six weeks, Patient A shows significant improvement with minimal side effects, while Patient B reports no benefit and experiences severe gastrointestinal distress. Assuming equal adherence to the medication, which factor best explains this significant divergence in response and tolerability?

  1. Fundamental differences in the severity of their underlying psychosocial stressors.
  2. A markedly stronger placebo response in Patient A compared to Patient B.
  3. Genetic variations in cytochrome P450 enzymes that affect the rate of drug metabolism. (correct answer)
  4. Patient B's rapid development of physiological tolerance to the medication's therapeutic effects.
Explanation: The correct answer is C. This scenario illustrates the concept of pharmacogenetics. Individuals have genetic variations in enzymes, such as the cytochrome P450 (CYP) family, which are responsible for metabolizing most drugs. Patient B may be a 'poor metabolizer' due to their specific CYP2D6 or CYP2C19 genotype. This would cause the drug to be cleared slowly, leading to high plasma concentrations, a lack of efficacy (as the brain adapts to the high levels), and an increase in side effects. Patient A may be a 'normal metabolizer.' (A) and (B) are factors in treatment response but do not explain the physiological difference in side effects as well as a metabolic difference does. (D) is incorrect; tolerance would imply an initial positive effect that fades, which is not what is described.

Question 12

A patient with generalized anxiety disorder reports that their new prescription for clonazepam has been very effective. They request a long-term, indefinite prescription. A major concern that a responsible clinician should have regarding the chronic daily use of a benzodiazepine like clonazepam for anxiety is its:

  1. delayed therapeutic onset, which can frustrate patients seeking immediate relief.
  2. high potential for causing physiological dependence and a difficult withdrawal syndrome. (correct answer)
  3. known interaction with tyramine-containing foods, leading to a hypertensive crisis.
  4. tendency to cause irreversible movement disorders like tardive dyskinesia with extended use.
Explanation: The correct answer is B. The primary limitation and concern for long-term daily use of benzodiazepines is the high risk of developing tolerance (requiring higher doses for the same effect) and physiological dependence. Abrupt cessation after long-term use can lead to a severe and sometimes dangerous withdrawal syndrome. (A) is incorrect; benzodiazepines have a very rapid onset of action, which is part of their appeal. (C) is incorrect; the tyramine interaction is characteristic of MAOI antidepressants, not benzodiazepines. (D) is incorrect; tardive dyskinesia is associated with long-term use of antipsychotic medications.

Question 13

Tricyclic antidepressants (TCAs) such as amitriptyline are now considered second- or third-line treatments for depression, despite their established efficacy. Why are selective serotonin reuptake inhibitors (SSRIs) generally preferred over TCAs as a first-line treatment in contemporary practice?

  1. TCAs have a significantly higher potential for abuse and psychological dependence compared to SSRIs.
  2. The therapeutic effects of TCAs take much longer to appear compared to the more rapid action of SSRIs.
  3. TCAs affect multiple neurotransmitter systems, leading to a higher burden of side effects and greater lethality in overdose. (correct answer)
  4. TCAs have been shown to be less effective than SSRIs in treating severe or melancholic subtypes of depression.
Explanation: The correct answer is C. TCAs are relatively 'dirty' drugs, meaning they interact with many different receptors in addition to blocking serotonin and norepinephrine reuptake. They also block muscarinic cholinergic, histamine H1, and alpha-1 adrenergic receptors, which leads to a wide range of side effects (dry mouth, sedation, weight gain, orthostatic hypotension). Crucially, they are cardiotoxic and highly lethal in overdose, unlike SSRIs. This poor side-effect and safety profile is the primary reason for their decline in use. (A) is incorrect as neither has significant abuse potential. (B) is incorrect as both classes have a similar delayed onset of action. (D) is incorrect; TCAs are often considered equally or even more effective for severe depression, but their risks outweigh their benefits for most patients.

Question 14

A patient is prescribed a medication that is described as a 'GABA-A receptor positive allosteric modulator.' The patient takes the medication and reports a significant reduction in anxiety. Which of the following best explains how this drug achieves its effect at a conceptual level?

  1. It directly mimics GABA and binds to the same site on the receptor to open the chloride ion channel.
  2. It permanently alters the structure of the GABA-A receptor, making it more sensitive to GABA.
  3. It blocks the reuptake of GABA from the synapse, increasing its overall concentration.
  4. It binds to a different site on the receptor, increasing the effect of GABA when GABA itself binds. (correct answer)
Explanation: When you encounter questions about neurotransmitter receptor mechanisms, focus on understanding how different drugs can influence the same receptor system through distinct pathways. The term "positive allosteric modulator" is your key clue here—it tells you exactly how the drug works. GABA-A receptors are ligand-gated chloride channels that produce inhibitory effects when activated, which explains why enhancing their function reduces anxiety. A positive allosteric modulator doesn't replace GABA or change GABA levels—instead, it makes the receptor more responsive to GABA when GABA is already present. The drug binds to an allosteric site (a location separate from where GABA binds) and enhances GABA's natural effect, making answer D correct. Let's examine why the other options miss the mark. Answer A describes a direct GABA agonist that would bind to GABA's binding site and mimic its action—this isn't allosteric modulation. Answer B suggests permanent structural changes, but allosteric modulators work reversibly and don't permanently alter receptor structure. Answer C describes a reuptake inhibitor mechanism, which would increase GABA concentration in the synapse rather than modifying receptor sensitivity. Remember this pattern: "allosteric modulator" always means the drug binds to a site different from the natural neurotransmitter's binding site. Positive modulators enhance the neurotransmitter's effect, while negative modulators diminish it. This distinction frequently appears on psychology exams when testing psychopharmacology concepts.

Question 15

A new drug for depression is found to significantly prolong the duration that serotonin remains in the synaptic cleft, thereby increasing the activation of postsynaptic receptors. Laboratory studies confirm that the drug molecule does not bind directly to any serotonin receptors, nor does it alter the function of the enzymes that catabolize serotonin. How is this drug most likely classified?

  1. A direct serotonin agonist
  2. A selective serotonin reuptake inhibitor (SSRI) (correct answer)
  3. A monoamine oxidase inhibitor (MAOI)
  4. A serotonin releasing agent
Explanation: The correct answer is B. The description matches the mechanism of an SSRI, which works by binding to the presynaptic serotonin transporter protein, blocking the reuptake of serotonin from the synapse and thus increasing its availability. (A) is incorrect because a direct agonist would bind to and activate postsynaptic receptors. (C) is incorrect because an MAOI would inhibit the enzyme (monoamine oxidase) that breaks down serotonin, which the stem explicitly rules out. (D) is incorrect because a releasing agent would actively promote the release of serotonin from the presynaptic terminal, a different mechanism.

Question 16

After several years of pharmacotherapy for a chronic psychotic disorder, a patient develops involuntary, repetitive movements of the facial muscles, including grimacing, lip-smacking, and tongue protrusion. These movements persist even after the medication is discontinued. Which of the following treatments is the most likely cause of this condition?

  1. Long-term use of a first-generation antipsychotic like haloperidol. (correct answer)
  2. High-dose therapy with a benzodiazepine like lorazepam.
  3. Chronic treatment with a mood stabilizer like lithium.
  4. An overdose of a selective serotonin reuptake inhibitor (SSRI) like fluoxetine.
Explanation: The correct answer is A. The symptoms described are characteristic of tardive dyskinesia (TD), a serious and often irreversible movement disorder. TD is a well-known risk associated with long-term use of dopamine receptor antagonists, particularly the older, first-generation (or 'typical') antipsychotics. (B) is incorrect; while benzodiazepines can cause dependence and withdrawal, they do not cause tardive dyskinesia. (C) is incorrect; lithium toxicity can cause tremor and other neurological signs, but not the classic oro-buccal-lingual dyskinesia of TD. (D) is incorrect; an SSRI overdose is associated with serotonin syndrome, not TD.

Question 17

A patient is prescribed alprazolam (half-life ≈ 12 hours) for occasional panic attacks, and another patient is prescribed fluoxetine (half-life ≈ 5 days) for major depressive disorder. Both patients take their medication once daily and both accidentally miss a single dose. Which outcome is most probable based on the pharmacokinetics of these drugs?

  1. The alprazolam patient is more likely to experience acute withdrawal symptoms and a recurrence of anxiety. (correct answer)
  2. The fluoxetine patient will experience a more severe discontinuation syndrome than the alprazolam patient.
  3. Both patients are likely to experience significant adverse effects of equal severity due to the missed dose.
  4. The fluoxetine patient is more likely to experience a rebound of depressive symptoms within 24 hours.
Explanation: The correct answer is A. A drug's half-life determines how quickly its concentration in the plasma decreases. Alprazolam's short half-life means its levels will drop significantly after missing one dose, leading to potential inter-dose withdrawal or rebound anxiety. Fluoxetine's very long half-life provides a 'tapering' effect, so a single missed dose will cause only a very small drop in plasma concentration, making immediate effects unlikely. (B) and (D) are incorrect because the long half-life of fluoxetine protects against immediate effects from a missed dose. (C) is incorrect because the difference in half-life will lead to very different outcomes.

Question 18

A psychiatrist chooses to prescribe a second-generation (atypical) antipsychotic, such as risperidone, over a first-generation (typical) antipsychotic, such as haloperidol, for a patient with newly diagnosed schizophrenia. This decision is most likely motivated by the significantly lower risk of which side effect with risperidone?

  1. Metabolic syndrome, including weight gain and hyperglycemia.
  2. Anticholinergic effects, such as dry mouth and blurred vision.
  3. Extrapyramidal symptoms, such as drug-induced parkinsonism and dystonia. (correct answer)
  4. Agranulocytosis, a severe and life-threatening drop in white blood cells.
Explanation: The correct answer is C. The primary pharmacological distinction and clinical advantage of second-generation antipsychotics (SGAs) over first-generation antipsychotics (FGAs) is their lower affinity for dopamine D2 receptors and simultaneous activity at serotonin 5-HT2A receptors. This mechanism is believed to be responsible for their significantly lower risk of causing extrapyramidal symptoms (EPS), which include parkinsonism, dystonia, akathisia, and tardive dyskinesia. (A) is incorrect; many SGAs carry a higher risk of metabolic side effects than FGAs. (B) is a possible side effect of both classes, not the key differentiator. (D) is a specific, rare risk most strongly associated with clozapine, an SGA, but not a general feature differentiating the classes.

Question 19

A patient who has been stable on a high dose of the SSRI fluoxetine for depression decides to also start taking an over-the-counter herbal supplement, St. John's Wort, which also has serotonergic properties. A few days later, they present to the emergency department with confusion, agitation, muscle twitching (myoclonus), shivering, and a high fever. This clinical picture is most indicative of:

  1. Neuroleptic malignant syndrome.
  2. Serotonin syndrome. (correct answer)
  3. Antidepressant discontinuation syndrome.
  4. A paradoxical anxiety reaction.
Explanation: The correct answer is B. This is a classic presentation of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system. It is often caused by combining two or more serotonergic drugs, such as an SSRI and St. John's Wort. The symptoms form a triad of cognitive changes (confusion, agitation), autonomic instability (fever, shivering), and neuromuscular hyperactivity (myoclonus). (A) is incorrect; NMS is associated with antipsychotics and characterized by lead-pipe rigidity. (C) is incorrect as it's caused by stopping, not adding, a medication. (D) is incorrect as the symptom cluster, particularly the fever and myoclonus, points to a systemic toxicity rather than a purely psychological reaction.

Question 20

A patient with bipolar disorder who is prescribed lithium carbonate must undergo regular blood tests to measure its plasma concentration. This frequent monitoring is critical primarily because lithium:

  1. is metabolized erratically by the liver, causing unpredictable fluctuations in drug level.
  2. has a narrow therapeutic window, meaning the effective dose is close to the toxic dose. (correct answer)
  3. often leads to rapid tolerance, requiring frequent dose increases to maintain its effect.
  4. is only effective when its active metabolites, not the parent drug, reach a target concentration.
Explanation: The correct answer is B. Lithium has a very narrow therapeutic index (or window), which means that the range between the minimum effective concentration and the minimum toxic concentration is small. Small changes in dose or in the body's ability to excrete lithium (e.g., due to dehydration or kidney problems) can shift the level from therapeutic to toxic, causing serious side effects. (A) and (D) are incorrect; lithium is an element and is not metabolized by the liver. It is excreted unchanged by the kidneys. (C) is incorrect; while some adaptation may occur, rapid tolerance requiring frequent dose escalation is not the primary reason for blood monitoring; safety is.